Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Outlook Therapeutics, Inc. OTLK
$1.15
+$0.02 (1.77%)
На 18:01, 12 мая 2023
+769.57%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
293883724.00000000
-
week52high
1.70
-
week52low
0.68
-
Revenue
0
-
P/E TTM
-4
-
Beta
0.63875400
-
EPS
-0.33000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 12:30
Описание компании
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 27 авг 2020 г. |
| Oppenheimer | Outperform | Outperform | 18 авг 2020 г. |
| HC Wainwright & Co. | Buy | 27 мая 2020 г. | |
| Ladenburg Thalmann | Buy | 11 сент 2019 г. | |
| H.C. Wainwright | Buy | Buy | 18 июл 2019 г. |
| Chardan Capital | Buy | 13 сент 2022 г. | |
| BTIG | Buy | 31 окт 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 06 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Evanson Jeff | D | 745975 | 267000 | 20 янв 2023 г. |
| Evanson Jeff | D | 1012975 | 103255 | 19 янв 2023 г. |
| Evanson Jeff | D | 1116230 | 33738 | 18 янв 2023 г. |
| Evanson Jeff | D | 1149968 | 27162 | 17 янв 2023 г. |
| Sukhtian Ghiath M. | A | 70047204 | 14230418 | 28 дек 2022 г. |
| Sukhtian Faisal Ghiath | A | 68000 | 30000 | 07 окт 2022 г. |
| Haddadin Yezan Munther | A | 63343 | 3600 | 07 окт 2022 г. |
| Haddadin Yezan Munther | A | 59743 | 29743 | 06 окт 2022 г. |
| Haddadin Yezan Munther | A | 71998 | 71998 | 05 окт 2022 г. |
| Gangolli Julian S | A | 74398 | 74398 | 05 окт 2022 г. |
Новостная лента
Outlook Therapeutics: August PDUFA For Wet AMD Blockbuster
Seeking Alpha
28 апр 2023 г. в 17:58
Oncobiologics, born in pursuit of oncology biosimilars, dramatically shifted its outlook, appropriately rechristening itself as Outlook Pharmaceuticals. Outlook has set its sights full bore on treatment of retinal diseases.
Outlook Therapeutics® to Present at the H.C. Wainwright BioConnect Investor Conference
GlobeNewsWire
27 апр 2023 г. в 08:05
Russ Trenary, President and Chief Executive Officer and Glen Olsheim, Executive Director, Commercial Excellence of Outlook Therapeutics to participate in a live moderated fireside chat on Tuesday, May 2nd at 2:00 PM ET Russ Trenary, President and Chief Executive Officer and Glen Olsheim, Executive Director, Commercial Excellence of Outlook Therapeutics to participate in a live moderated fireside chat on Tuesday, May 2nd at 2:00 PM ET
Outlook Therapeutics ends 1Q with cash and equivalents of $52.3M; says it has sufficient capital into 4Q 2023
Proactive Investors
14 февр 2023 г. в 09:42
Outlook Therapeutics Inc (NASDAQ:OTLK) announced that it has ended its first quarter of fiscal 2023 with cash and equivalents of $52.3 million as of December 31, 2022, which the company says is expected to provide sufficient capital to support operations past the anticipated US Food & Drug Administration (FDA) approval of ONS-5010 in the third calendar quarter of 2023 and into the fourth calendar quarter of 2023. The biopharmaceutical firm also noted that pre-launch commercial activities are underway as the company advances toward the FDA Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023, for ONS-5010/LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation for the treatment of wet age-related macular degeneration (wet AMD).
Outlook Therapeutics strengthens medical affairs and commercial expertise with new appointments
Proactive Investors
19 янв 2023 г. в 09:01
Outlook Therapeutics Inc (NASDAQ:OTLK) has announced the appointments of Dr Surendra Sharma as senior vice president of medical affairs and Glen Olsheim as executive director of commercial excellence as it grows its leadership team. The biopharmaceutical company said Sharma has more than 15 years of experience in the pharmaceutical and biotechnology industries leading corporate alliances among research and development (R&D), commercial, marketing and business stakeholders.
Outlook Therapeutics plots course for wet AMD drug approval in year-end shareholder letter
Proactive Investors
29 дек 2022 г. в 12:06
Outlook Therapeutics Inc (NASDAQ:OTLK) has announced financial results for its fiscal year ended September 30 and laid out plans for 2023 in an end-of-year letter. “Our fiscal year 2022 laid a solid foundation for what we believe will be a transformational 2023,” CEO Russell Trenary III said.